Evidence map›Paper›PMID 29329358›Full record

ArticleAmerican journal of hypertension2018

Modulating Role of Ang1-7 in Control of Blood Pressure and Renal Function in AngII-infused Hypertensive Rats.

Marta Kuczeriszka, Elzbieta Kompanowska-Jezierska, Janusz Sadowski, Minolfa C Prieto, L Gabriel Navar

Open access · bronzeAbstract read
In one paragraph

Article in American journal of hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Kidney dopamine DAmerican journal of physiology. Renal physiology · 2019
    Article
  7. Article
  8. Article
  9. Dimerization of ATCurrent hypertension reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Marta KuczeriszkaDepartment of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Pol.
Elzbieta Kompanowska-JezierskaDepartment of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Pol.
Janusz SadowskiDepartment of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Pol.
Minolfa C PrietoDepartment of Physiology, School of Medicine, Tulane University, New Orleans, Louisiana, USA.
L Gabriel NavarDepartment of Physiology, School of Medicine, Tulane University, New Orleans, Louisiana, USA.
Polish Academy of Sciences · PLTulane University · USMossakowski Medical Research Institute, Polish Academy of Sciences · PL

Funding

Translational Research in Hypertension and Renal BiologyP30GM103337 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI NAVAR, LUIS GABRIEL · 2012 to 2016
$5.8M
Renal Function Derangements in HypertensionR01HL026371 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NAVAR, LUIS GABRIEL · 1985 to 2010
$3.4M
NHLBI NIH HHS R01 HL026371NIGMS NIH HHS P30 GM103337
6 · The paper itself

Abstract

backgroundIndirect evidence suggests that angiotensin 1-7 (Ang1-7) may counterbalance prohypertensive actions of angiotensin II (AngII), via activation of vascular and/or renal tubular receptors to cause vasodilation and natriuresis/diuresis. We examined if Ang1-7 would attenuate the development of hypertension, renal vasoconstriction, and decreased natriuresis in AngII-infused rats and evaluated the mechanisms involved.

methodsAngII, alone or with Ang1-7, was infused to conscious Sprague-Dawley rats for 13 days and systolic blood pressure (SBP) and renal excretion were repeatedly determined. In anesthetized rats, acute actions of Ang1-7 and effects of blockade of angiotensin AT1 or Mas receptors (candesartan or A-779) were studied.

resultsChronic AngII infusion increased SBP from 143 ± 4 to 195 ± 6 mm Hg. With Ang1-7 co-infused, SBP increased from 133 ± 5 to 161 ± 5 mm Hg (increase reduced, P < 0.002); concurrent increases in urine flow (V) and sodium excretion (UNaV) were greater. In anesthetized normotensive or AngII-induced hypertensive rats, Ang1-7 infusion transiently increased mean arterial pressure (MABP), transiently decreased renal blood flow (RBF), and caused increases in UNaV and V. In normotensive rats, candesartan prevented the Ang1-7-induced increases in MABP and UNaV and the decrease in RBF. In anesthetized normotensive, rats intravenous A-779 increased MABP (114 ± 5 to 120 ± 5 mm Hg, P < 0.03) and urine flow. Surprisingly, these changes were not observed with A-779 applied during background Ang1-7 infusion.

conclusionsThe results suggest that in AngII-dependent hypertension, Ang1-7 deficit contributes to sodium and fluid retention and thereby to BP elevation; a correction by Ang1-7 infusion seems mediated by AT1 and not Mas receptors.

Indexed as

Angiotensin IIAngiotensin IAnimalsAntihypertensive AgentsBlood PressureDisease Models, AnimalHypertensionMaleNatriuresisPeptide FragmentsProto-Oncogene MasProto-Oncogene ProteinsRats, Sprague-DawleyReceptor, Angiotensin, Type 1Receptors, G-Protein-CoupledSignal TransductionAngiotensin Iangiotensin I (1-7)Angiotensin IIAntihypertensive AgentsPeptide FragmentsProto-Oncogene MasProto-Oncogene ProteinsReceptor, Angiotensin, Type 1Receptors, G-Protein-Coupled

Identifiers

PMID29329358
PMCPMC5861538
OpenAlexW2783990244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.